Upadacitinib associated with normalisation of HRQoL in UC

Upadacitinib was associated with higher rates of normalisation of health-related quality-of-life (HRQoL) in participants with moderately to severely active ulcerative colitis (UC) compared with placebo in a post-hoc analysis of the phase 3 U-ACHIEVE and U-ACCOMPLISH studies.

The phase 3 U-ACHIEVE (NCT02819635) and U-ACCOMPLISH (NCT03653026) studies showed that upadacitinib is a safe and efficacious therapy for participants with moderately to severely active UC [1,2]. Dr Joana Torres (Hospital Beatriz Ângelo, Portugal) presented a post-hoc analysis of these 2 studies, highlighting the effects of 8-week induction and 52-week maintenance treatments with upadacitinib on HRQoL outcomes [3].

The analysis showed that the normalisation of the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) was achieved by 54.1% of the participants on upadacitinib induction therapy, compared with 33.2% of those on placebo (P<0.001). The corresponding rates for the Inflammatory Bowel Disease Questionnaire (IBDQ) were 61.6% versus 25.9% (P<0.001), for the physical component summary of 36-Item Short Form (SF-36) Health Survey were 55.9% versus 32.3% (P<0.001), and for the EuroQol 5-Dimension 5-level (EQ-5D-5L) were 45.1% versus 20.7% (P<0.001). Similar results were observed for upadacitinib maintenance therapy.

“If we look at a composite HRQoL endpoint, for which participants needed to have normalisation across all the HRQoL measures, we notice that still a substantial proportion of participants on upadacitinib induction therapy achieved this outcome [18.9%] compared with those on placebo [5.5%; P<0.001],” added Prof. Torres. The corresponding rates for maintenance therapy were 22.3% for upadacitinib 15 mg, 24% for upadacitinib 30 mg, and 8.7% for placebo (P<0.001 for both comparisons).

“These findings suggest that upadacitinib may help patients with moderately to severely active UC to achieve the long-term treatment goal of HRQoL normalisation,” concluded Dr Torres.

1. 
   
   1. Danese S, et al. Lancet. 2022;399:2113-2128.
   2. Vermeire S, et al. Lancet Gastroenterol Hepatol. 2023;8(11):976-989.
   3. Torres J, et al. Normalisation of health-related quality of life outcomes in patients with moderately to severely active ulcerative colitis treated with Upadacitinib: a post-hoc analysis of phase 3 U-ACHIEVE and U-ACCOMPLISH studies. OP103, UEG Week 2024, 12–15 October, Vienna, Austria.

Copyright ©2024 Medicom Medical Publishers



Posted on 28 November 2024